STERICALLY STABILIZED AMPHOTERICIN B-LIPOSOMES - TOXICITY AND BIODISTRIBUTION IN MICE

被引:26
作者
VANETTEN, EWM [1 ]
VANVIANEN, W [1 ]
TIJHUIS, RHG [1 ]
STORM, G [1 ]
BAKKERWOUDENBERG, IAJM [1 ]
机构
[1] UNIV UTRECHT,DEPT PHARMACEUT,UTRECHT,NETHERLANDS
关键词
AMPHOTERICIN B; BIODISTRIBUTION; TOXICITY; LIPOSOME; POLY(ETHYLENE GLYCOL);
D O I
10.1016/0168-3659(95)00071-F
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this study it was investigated whether long-circulating amphotericin B (AMB) containing liposomes could be prepared by incorporation of polyethylene glycol (1900) derivatized distearoylphosphatidylethanolamine (PEG-DSPE), and whether the incorporation of PEG-DSPE affected toxicity and biodistribution of the preparation in mice. Toxicity of two formulations of liposomes containing both PEG-DSPE and AMB (PEG-AMB-LIP, types 1 and 2) was compared with that of AMB-liposomes without PEG-DSPE (AMB-LIP) as well as that of MB-deoxycholate (AMB-DOC). The maximum tolerated dosage (MTD) of AMB-DOC, expressed in terms of death during treatment for 5 consecutive days or significant increases in the parameters used to monitor renal and hepatic functions, was 0.8 mg/kg per day. AMB-LIP were the least toxic, the MTD being 11 mg/kg per day. The formulation with AMB complexed to DSPG (PEG-AMB-LIP type 1) was as toxic as AMB-DOC. This PEG-AMB-LIP formulation was omitted from further studies on biodistribution. With AMB complexed to PEG-DSPE (PEG-AMB-LIP type 2) toxicity was substantially reduced, resulting in a MTD of 9 mg/kg per day. Biodistribution of radiolabeled PEG-AMB-LIP type 2 was compared with that of AMB-LIP. Blood residence time of PEG-AMB-LIP type 2 was prolonged as compared to AMB-LTP; For PEG-AMB-LIP type 2 at 24 h after administration 30% of the injected dosage of AMB in intact liposomes was circulating versus 6% for AMB-LIP.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 24 条
[1]  
Allen T.M., 2008, J LIPOSOME RES, V2, P289, DOI [10.3109/08982109209010210, DOI 10.3109/08982109209010210]
[2]   SUBCUTANEOUS ADMINISTRATION OF LIPOSOMES - A COMPARISON WITH THE INTRAVENOUS AND INTRAPERITONEAL ROUTES OF INJECTION [J].
ALLEN, TM ;
HANSEN, CB ;
GUO, LSS .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1150 (01) :9-16
[3]   PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE [J].
ALLEN, TM ;
HANSEN, C .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) :133-141
[4]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[5]  
AMES BN, 1960, J BIOL CHEM, V235, P769
[6]  
BAKKERWOUDENBER.IA, 1993, J INFECT DIS, V168, P164
[7]  
BAKKERWOUDENBER.IA, 1992, BIOCHIM BIOPHYS ACTA, V1138, P318
[8]   SPECIFIC TARGETING WITH POLY(ETHYLENE GLYCOL)-MODIFIED LIPOSOMES - COUPLING OF HOMING DEVICES TO THE ENDS OF THE POLYMERIC CHAINS COMBINES EFFECTIVE TARGET BINDING WITH LONG CIRCULATION TIMES [J].
BLUME, G ;
CEVC, G ;
CROMMELIN, MDJA ;
BAKKERWOUDENBERG, IAJM ;
KLUFT, C ;
STORM, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1149 (01) :180-184
[9]   LIPOSOMES FOR THE SUSTAINED DRUG RELEASE INVIVO [J].
BLUME, G ;
CEVC, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) :91-97
[10]  
Gabizon A., 1988, J LIPOSOME RES, V1, P123, DOI DOI 10.3109/08982108809035986